EICHORCondition: Weight Loss · Sponsor: Viking Therapeutics, Inc.
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once weekly.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Age ≥18 years of age at the time of signing the informed consent 2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI \<50 kg/m2 Exclusion Criteria: 1. History of or current clinically significant medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation 2. Self-reported body weight change of 5% or more within 3 months of screening 3. Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational) 4. Current or past diagnosis of chronic pancreatitis 5. Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened) 6. Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening 7. Any prescription or over-the-counter medications intended for weight loss within 6 months of screening
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Viking Clinical Site #119 | Birmingham, Alabama, United States | — |
| Viking Clinical Site #114 | Long Beach, California, United States | — |
| Viking Clinical Site #110 | Los Angeles, California, United States | — |
| Viking Clinical Site #113 | Tustin, California, United States | — |
| Viking Clinical Site #116 | Clearwater, Florida, United States | — |
| Viking Clinical Site #106 | Clearwater, Florida, United States | — |
| Viking Clinical Site #112 | Jacksonville, Florida, United States | — |
| Viking Clinical Site #105 | Ocoee, Florida, United States | — |
| Viking Clinical Site #107 | Port Orange, Florida, United States | — |
| Viking Clinical Site #104 | Indianapolis, Indiana, United States | — |
| Viking Clinical Site #103 | Louisville, Kentucky, United States | — |
| Viking Clinical Site #109 | Marrero, Louisiana, United States | — |
+ 8 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06068946